Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Massachusetts General Hospital
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06136546CT.gov Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Inflammatory Disease
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Infliximab (this asset) | Massachusetts General Hospital | P2 | CCC · 53 |
| Vildagliptin | Rio de Janeiro State University | P4 | BB |
| Methoxy Polyethylene Glycol-Epoetin Beta | Taipei Veterans General Hospital, Taiwan | P4 | BB |
| Pitavastatin | Aichi Gakuin University | P4 | BB |
| Sitagliptin | University of Southern California | P3 | BB |
| Sufentanyl | The First Affiliated Hospital with Nanjing Medical University | P4 | BB |
| Oxycodone | The First Affiliated Hospital with Nanjing Medical University | P4 | B |
| Pioglitazone | National Institute on Aging (NIA) | P4 | B |
| Riluzole | Emory University | P4 | B |
+42 more in the Inflammatory Disease cohort
Other indications for Infliximab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatosplenic T-Cell Lymphoma | — | P4 | BB · 64 |
| Colitis | — | P2 | B · 63 |
| Crohn Disease | — | P3 | B · 61 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Infliximab in Inflammatory Disease. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/infliximab-inflammatory-disease
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →